This section contains news items that were not issued as a press release.
- Thursday, 12 April 2012
- AstraZeneca and Liverpool School of Tropical Medicine combine resources in the fight against Neglected Tropical Diseases AstraZeneca and the Liverpool School of Tropical Medicine announce a research agreement aimed at finding new medicines to treat river blindness and lymphatic filariasis, which are neglected tropical diseases (NTDs) that affect millions of people.
- Thursday, 12 April 2012
- AstraZeneca and DNDi to Collaborate on Drug Screening for Neglected Tropical Diseases AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
- Thursday, 5 April 2012
- Collaboration’s exciting discovery could be novel drug target A first-class collaboration between AstraZeneca and academia, Karolinska Institute, has resulted in a breakthrough discovery published in the Journal of Biological Chemistry.
- Monday, 2 April 2012
- AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio AstraZeneca and Amgen today announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
- Monday, 12 March 2012
- AstraZeneca and Nobel Media bring Nobel Laureate Peter Doherty to India The AstraZeneca Nobel Medicine Initiative visits India for the first time.
- Tuesday, 7 February 2012
- AstraZeneca Appoints Dr. Mike Poole to Lead New ‘Virtual’ Neuroscience Innovative Medicines Unit AstraZeneca today announced the appointment of Dr. Mike Poole to lead its newly created virtual Neuroscience Innovative Medicines Unit (iMed) with the responsibility for a portfolio of large and small molecule projects.
- Thursday, 2 February 2012
- AstraZeneca Fourth quarter and full year results 2011 AstraZeneca R&D President Martin Mackay discusses discusses R&D performance and productivity during company's 2011 full-year and fourth quarter results.
- Thursday, 2 February 2012
- AstraZeneca and Karolinska Institutet to create new Translational Sciences Centre TestAstraZeneca and the Swedish medical university Karolinska Institutet today announced plans to create a Translational Sciences Centre that aims to discover and deliver biomarkers for clinical use across AstraZeneca’s drug discovery and early development organisation (called Innovative Medicines). The Translational Sciences Centre builds on a longstanding relationship between the two organisations and will be based at the university’s campus in Stockholm.
- Thursday, 26 January 2012
- AstraZeneca and Karolinska Institutet PET Centre Announce Molecular Imaging Research Agreement AstraZeneca and Karolinska Institutet today announced a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience research and development pipeline.
- Tuesday, 10 January 2012
- Dr. Briggs Morrison to join AstraZeneca R&D; Dr. Anders Ekblom to lead new Science and Technology function AstraZeneca is pleased to announce the appointment of industry leading drug development expert, Dr. Briggs Morrison, to the position of Executive Vice President Global Medicines Development (GMD) reporting to the President of R&D, Dr. Martin Mackay.